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An overview of prognostic factors in small cell lung cancer
A report from the Subcommittee for the Management of Lung Cancer*
of the United Kingdom Coordinating Committee on Cancer Research
N.S.B. Rawsont & J. Peto
Section of Epidemiology, Institute of Cancer Research, Block D, 15 Cotswold Road, Sutton, Surrey SM2 SNG, UK.
Summary Several studies of small cell lung cancer (SCLC) treatments have been performed in the United
Kingdom. In some, prognostic factor analyses were carried out but the results were not entirely consistent.
The Lung Cancer Subcommittee of the United Kingdom Coordinating Committee on Cancer Research
(UKCCCR) consequently initiated an overview of these studies with the aim of identifying the important
prognostic factors using a large number of patients. Information on almost 4,000 patients was available, but it
was necessary to perform analyses on smaller subsets because the variables recorded in individual studies were
inconsistent. A number of variables contributed significantly to the prediction of likely survival over the 6
months after starting treatment, but performance status (PS), alkaline phosphatase (AlkP) and disease stage
were shown to be the most important; aspartate aminotransferase (AST) and lactate dehydrogenase (LDH)
may also be useful. A prognostic index was devised for this initial period and validated using independent
data. For patients who survived the first 6 months, the pre-treatment variables important for prognosis in the
6-24 month period were stage, PS and plasma sodium (Na). The Subcommittee recommends that perfor-
mance status, disease stage, AlkP, Na, AST and LDH should be measured in all future SCLC studies to assist
comparisons between studies and possibly the selection of patients for different treatment strategies. The
additional recording of five other variables would allow a more definitive overview to be performed at some
future date.
Small cell lung cancer (SCLC) is a disease in which long-term
survivors are few, the majority of patients dying within 2
years of diagnosis. Nevertheless, the identification of factors
that predict likely survival, especially in the short-term, is of
clinical importance since the treatment administered to a
patient may depend on the prediction.
A number of studies of SCLC treatments have been car-
ried out in the United Kingdom (Allan et al., 1984; Cullen et
al., 1986; MRC Lung Cancer Working Party, 1979, 1981,
1983, 1989a, b; Smyth et al., 1986; Souhami et al., 1984;
Thatcher et al., 1982, 1985a, b, 1987). In some of these,
analyses to determine important prognostic factors were also
performed (Cerny et al., 1987; MRC Lung Cancer Working
Party, 1981, 1983, 1989a, b; Souhami et al., 1985; Vincent et
al., 1987). Several variables were demonstrated to be of
importance in prognosis; these included performance status,
disease stage, serum alkaline phosphatase (AlkP), plasma
sodium (Na), serum albumin, serum lactate dehydrogenase
(LDH), serum alanine aminotransferase (ALT), blood bicar-
bonate and age. However, the variables recorded and the
methods of analysis differed between the studies, and the
results were not entirely consistent.
To identify the important prognostic factors using a much
larger number of patients than was available in the individual
studies, the Subcommittee for the Management of Lung
Cancer of the United Kingdom Coordinating Committee on
*Members: Professor J.F. Smyth (chairman), Dr N. Thatcher
(secretary), Dr D.V. Ash, Professor N.M. Bleehan, Dr. R.L. Carter,
Mr P. Goldstraw, Professor S.B. Kaye, Professor J. Peto, Dr I.E.
Smith, Dr S. Spiro, Miss D. Watson, Dr J.R. Yarnold, and observers
from the Cancer Research Campaign, the Department of Health, the
Marie Curie Memorial Foundation, the Medical Research Council,
the Scottish Home and Health Department and the Tenovus Ins-
titute for Cancer Research.
tPresent address: Psychiatric Pharmacoepidemiology Research con-
sortium, Applied Research, University of Saskatchewan, Box 92,
University Hospital, Saskatoon, Saskatchewan, S7N OXO, Canada.
Correspondence: J. Peto.
Received 17 July 1989; and in revised form 16 November 1989.
Cancer Research (UKCCCR) initiated an overview of United
Kingdom SCLC studies. The participating centres supplied
data sets on magnetic media to the Section of Epidemiology
at the Institute of Cancer Research for the analysis.
Patients and methods
Information on a total of 3,873 SCLC patients was received
from six centres as follows.
1. Results of four sequential studies, comprising a total of
434 patients treated in two hospitals, were received from the
CRC Department of Medical Oncology, Christie Hospital
and Holt Radium Institute, Manchester (Thatcher et al.,
1982, 1985a, b, 1987). Since it had been shown previously
that outcome was unrelated to treatment in these studies, the
results were included as one data set. Up to 61 variables were
recorded for each patient. LDH, disease stage, Na, Karnof-
sky performance status, AlkP and bicarbonate were reported
to be the main prognostic factors (Cerny et al., 1987).
2. Data from three non-randomised studies, comprising a
total of 297 patients, were received from the ICRF Medical
Oncology Unit, Western General Hospital, Edinburgh (Allan
et al., 1984; Smyth et al., 1986). There were no differences in
outcome between the three treatment regimes and, therefore,
the 297 patients were treated as one data set.
3. Data were received for 282 patients referred to the Lung
Unit at the Royal Marsden Hospital (RMH), Sutton, Surrey,
between 1978 and 1985. The patients were treated according
to a series of different chemotherapy protocols which ran
consecutively during this period, but outcome was not related
to any of the various treatments. Vincent et al. (1987) have
previously performed a prognostic factor analysis on these
data. They had 22 variables available for analysis, but
deliberately omitted disease stage from their multivariate
analysis. The evaluation of disease stage is often based on
time-consuming and elaborate investigations and the aim of
these authors was to devise a simple prognostic index ex-
cluding this variable. The multivariate analysis showed that
albumin, ALT and World Health Organization (WHO) per-
'." Macmillan Press Ltd., 1990Br. J. Cancer (1990), 61, 597-604
598 N.S.B. RAWSON & J. PETO
formance status were the most important prognostic factors.
However, these variables did not have any predictive value
for survival beyond one year, once that had been attained.
4. Results from two multicentre randomised clinical trials,
comprising 367 and 610 patients, were received from the
Department of Oncology, University College Hospital and
Middlesex School of Medicine, London (UCH). There was
no difference with regard to survival between the treatment
groups in the first trial (Souhami et al., 1984). When the
overview analysis was performed, the results from the second
were unpublished and the trials were treated as two separate
data sets (UCH1 and UCH2) in this work. (The results of the
second trial have recently appeared in print (Morittu et al.,
1989; Spiro et al., 1989) showing a difference in terms of
overall survival between one of the treatment options and the
other three. In retrospect, it may have been preferable to
include an additional variable to indicate which treatment
option was given in this trial). Eleven variables from the first
trial have been analysed previously and Karnofsky perfor-
mance status, AlkP, disease stage, Na and albumin were
found to be the main prognostic factors (Souhami et al.,
1985). In the second trial, patients who died within three
weeks of starting treatment were more likely to have a poor
performance status, raised AlkP, raised blood urea and low
albumin levels (Morittu et al., 1989).
5. Data on 312 patients included in a multicentre sequen-
tial study were received from the Midlands Small Cell Lung
Cancer Group, Queen Elizabeth Hospital, Birmingham
(Cullen et al., 1986). Ninety-three of the patients were subse-
quently entered into a randomised trial.
6. Data from four multicentre randomised clinical trials,
comprising 330, 193, 706 and 342 patients, were received
from the MRC Cardiothoracic Epidemiology Group, Bromp-
ton Hospital, London. Details of the first three have been
published (MRC Lung Cancer Working Party, 1979, 1981,
1983, 1989a, b), while the fourth is on-going and the data
received comprised those patients entered in the trial by early
1988.
The variables that were available in two or more data sets
are shown in Table I. The MRC data included only age, sex
and disease stage for all four of its trials, and an activity
status score, haemoglobin (Hb), white blood cell (WBC) and
platelet counts in three of the four (Table I); other
measurements were recorded by some of the participating
hospitals, but they were not computerised. Since the aim of
the overview was to assess as many potential prognostic
factors as possible, it was decided to exclude the MRC
studies. This decision was fortuitous because it was subse-
quently possible to use informaton on patients in two of the
MRC studies in a validation exercise. After excluding the
MRC studies, there remained a total of 2,302 patients from
the other six data sets. Survival data for seven patients were
incomplete and the prognostic variables that were measured
in each of the six data sets were not recorded for every
patient. The maximum number of patients included in any
prognostic analysis was 1,960.
Performance status was not measured in the same way in
each of the six data sets. In Manchester and UCH 1, the
Karnofsky scale (Karnofsky & Burchenal, 1949) was used,
while in the other four either the Eastern Cooperative
Oncology Group (ECOG) scale (Zubrod et al., 1960) or the
WHO scale (World Health Organization, 1979) was used.
Apart from minor differences in the wording of the
categories, the ECOG and WHO scales are the same, but the
Karnofsky scale is different. Therefore, the overall assessment
of performance status (PS) shown in Table II was devised
and used throughout the analysis.
The principal method of analysis used in this overview was
proportional hazards regression, which is a multiple regres-
sion technique for investigating the relationship between sur-
vival time and possible explanatory (prognostic) variables(Cox, 1972). Using this method, regression coefficients are
estimated and a prognostic index or 'Cox score', which is the
logarithm of the individual's predicted relative death rate,
can be calculated for each patient. A forward stepwise proce-
dure, in which independent variables are added to the regres-
sion equation one at a time, was used to identify the
significant prognostic factors. At each step, the independent
variable which gave the largest increase in log-likelihood was
entered into the model if the likelihood ratio test showed that
the variable significantly improved the goodness of fit (Lee,
1980). A significance level of 5% was set as the limit for
Table II Overall assessment of performance status
PS ECOG WHO Karnofsky
I 0,1 0,1 80-100
2 2,3 2,3 50-70
3 4 4 10-40
Table I Variables recorded in the 10 data sets
Manchester Edinburgh RMH UCH1 UCH2 Midlands MRCI MRC2 MRC3 MRC4Variabe n = 434 n = 297 n = 282 n = 367 n = 610 n = 312 n = 330 n = 193 n = 706 n = 342
Age Yes Yes Yes Yes Yes Yes Yes Yes Yes YesSex Yes Yes Yes Yes Yes Yes Yes Yes Yes YesDisease stage Yes Yes Yes Yes Yes Yes Yes Yes Yes YesPerformance status (PS) Yes Yes Yes Yes Yes Yes No Yes Yes YesSerum alkaline phosphatase Yes Yes Yes Yes Yes Yes No No No No(AlkP)
Plasma sodium (Na) Yes Yes Yes Yes Yes Yes No No No NoGamma glutamyl transpeptidase Yes Yesa Yes Yes Yes Yes No No No No(GGT)
Serum albumin Yes Yes Yes Yes Yes No No No No NoHaemoglobin (Hb) Yes Yes Yes Yes Yes No No Yes Yes YesWhite blood cells (WBC) Yes Yes Yes Yes Yes No No Yes Yes YesPlatelets Yes Yes Yes Yes Yes No No Yes Yes YesBlood urea Yes No No Yes Yes Yes No No No NoAspartate aminotransferase (AST) Yes Yes No Yes No No No No No NoPlasma potassium Yes Yes No Yes No No No No No NoAlanine aminotransferase (ALT) Yes No Yes Yes No No No No No NoSerum calcium Yes No Yes No No No No No No NoBlood bicarbonate Yes No No Yes No No No No No NoSerum protein Yes No No Yes No No No No No NoErythrocyte sedimentation rate Yes Yes No No No No No No No No(ESR)
Plasma chloride Yes Yes No No No No No No No NoSerum lactate dehydrogenase Yes Yes No No No No No No No No(LDH)
'Values for only 90 of these patients were recorded
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inclusion in the model. The results of this procedure were
checked by performing a backward stepwise analysis.
Seven variables (age, sex, disease stage, PS, AlkP, Na and
serum gamma glutamyl transpeptidase (GGT) were recorded
in all six data sets although, of these, GGT was measured in
only 90 (30%) of the 297 Edinburgh patients (Table I). A
further four variables were available in five of the data sets,
but most other measurements were recorded for relatively
few patients. To take account of this inconsistency of
variables measured in the studies and the fact that each
variable was not always recorded for each patient in the
relevant data set, nine analyses were performed on the fol-
lowing subsets in which the listed variables were all known:
A. Age, sex, stage, PS, AlkP and Na (1,960 patients). B. Age,
sex, stage, ED, PS, AlkP, Na and GGT (1,631 patients). C.
Age, sex, stage, PS, AlkP, Na, albumin, Hb, WBC and
platelet counts (1,452 patients). D. Age, sex, stage, PS, AlkP,
Na and blood urea (1,364 patients). E. Age, sex, stage, PS,
AlkP, Na, serum aspartate aminotransferase (AST) and
plasma potassium (940 patients). F. Age, sex, stage, PS,
AlkP, Na and ALT (674 patients). G. Age, sex, stage, PS,
AlkP, Na and serum calcium (683 patients). H. Age, sex,
stage, PS, AlkP, Na, bicarbonate and serum protein (520
patients). I. Age, sex, stage, PS, AlkP, Na, erythrocyte
sedimentation rate (ESR), LDH and plasma chloride (360
patients).
From a preliminary analysis, it was clear that most
variables were more strongly predictive of survival over the
first 6 months than over the subsequent 18 months.
Therefore, all analyses were divided into two components: an
analysis of deaths occurring during the first 6 months after
starting treatment (censoring those who were alive at the end
of this time period) and a further analysis including only
those patients who were alive at the end of the 6 month
period.
After each analysis to identify the significant prognostic
factors, the relevant subset was re-assessed to determine
whether a 'similar' level of discrimination could be obtained
with a smaller number of variables. There is no standard
technique for this procedure and, therefore, an empirical
method was adopted. The Cox scores were calculated from
the full model, i.e. that consisting of all the significant prog-
nostic factors, and these scores were used to divide the
patients into three equal-sized groups with 'better', 'medium'
or 'worse' prognosis. In the analyses of the initial 6 month
period, the degree of discrimination between the three prog-
nosis groups was assessed by calculating the 6 month survival
rate in each group. The model was then reduced by excluding
the factor that was the last to be entered by the forward
stepwise procedure and the Cox scores for this model were
calculated. The scores were again used to divide the patients
into three equal-sized groups and the degree of discrimina-
tion re-examined. If the three 6 months survival rates were all
within ± 2.5% of the respective survival rates obtained in
the full model, the degree of discrimination was considered to
be 'similar' and, thus, to be acceptable. This process was
repeated until one or more of the rates were outside this
limit. The 'reduced' model was taken to be the one with the
minimum number of variables for which the survival rates
were all within ± 2.5% of those obtained using the full
model. The same procedure was used to analyse the 2 year
survival rates of patients who survived at least 6 months.
Results
Table III summarises some of the information about the
patients in the six data sets. The median age of the Man-
chester patients was slightly lower than those of the other
patients and the proportion of the Manchester patients aged
65 years or more was approximately half that in the other
studies. The male:female ratio was approximately 2:1 in all
the data sets. The proportion of patients with extensive
disease (ED) ranged from 40.5% in Manchester to 74.5% in
the Midlands. The distributions of PS also varied con-
siderably, with a particularly low proportion of patients with
the 'best' PS score in the Manchester data. The 2 year
survival rates ranged from 1.9% in UCHI to 9.4% in Man-
chester with an overall rate of 5.9%. To take account of
differences between the studies, additional variables indicat-
ing to which data set each patient belonged were included in
all further analyses.
The variables found by the forward stepwise procedure to
be significant prognostic factors in the nine analyses des-
cribed above are shown in Table IV; the backward stepwise
procedure identified the same significant variables. In each
analysis, the 'reduced' model consists of the variables above
the horizontal line in the relevant column of the table.
Although all six variables in analysis A made a significant
contribution to the full model for the first 6 months, a
'similar' degree of discrimination was retained if the model
was reduced to one consisting of PS, AlkP and stage (Table
V). Table IV shows that, in four of the nine analyses of the
first 6 months (A, C, D and G), the model could be reduced
to these same three variables while still maintaining an
'acceptable' level of discrimination and, in addition, in
analysis F the model could be reduced to just PS and AlkP.
In analysis E the 'reduced' model consisted of PS, stage and
AST, while in analysis H it consisted of stage, PS and age.
However, the full model could not be reduced at all in
analyses B (model comprised PS, AlkP, stage, age, Na and
GGT) and I (PS, LDH, age, stage and chloride). Never-
theless, in analyses B, E, H and I the degree of discrimination
produced by a model consisting of PS, AlkP and stage was
'similar' to that of the original full model. In each of analyses
G-I only a relatively small number of patients could be
included and the 6 month survival rates in the three prognos-
tic groups (especially in the 'medium' and 'worse' groups)
were generally higher than those obtained in the other
analyses (Table V).
Table III Age, sex, disease stage, performance status and survival of patients in the six data sets
Manchester Edinburgh RMH UCHI UCH2 Midlands Overall
n = 434 n = 297 n = 282 n = 367 n = 610 n = 305 n = 2,295
Median age 59 62 63 63 62 61 61
Age range 23-72 29-78 30-80 41 -79 31 -74 34-77 23-80
% aged 65 or more 18.7% 39.7% 40.8% 41.5% 36.9% 33.6% 34.6%
Male 63.6% 62.0% 61.3% 68.9% 68.4% 71.3% 66.3%
Female 36.4% 38.0% 38.7% 31.1% 31.6% 28.7% 33.7%
Limited disease 59.5% 51.2% 41.8% 35.1% 32.1% 25.5% 40.5%
Extensive disease 40.5% 48.8% 58.2% 64.9% 67.9% 74.5% 59.5%
Performance status
1 6.9% 60.9% 64.1% 39.5% 73.7% 74.2% 51.0%
2 82.7% 39.1% 33.5% 53.9% 22.6% 25.5% 44.6%
3 10.4% 0.0% 2.5% 6.6% 3.7% 0.3% 4.4%
Two year survival rate 9.4% 5.4% 8.1% 1.9% 4.0% 8.9% 5.9%(95% confidence (6.7-12.2%) (2.8-8.0%) (4.1-12.1%) (0.5-3.3%) (2.4-5.5%) (5.3-12.6%) (4.9-6.9%)interval)
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Table IV Order of inclusion of the significant variables in the analyses
Analysis A B C D E F G H I
First 6 n = 1,960 n = 1,631 n = 1,452 n = 1,364 n = 940 n = 674 n = 683 n = 520 n = 360
months PS*** PS*** PS*** PS*** PS*** PS*** PS*** Stage*** PS***
log AlkP*** log AlkP*** log AlkP*** log AlkP*** Stage*** log AlkP*** log AlkP*** PS*** log LDH***
Stage*** Stage*** Stage*** Stage*** log AST*** Stage*** Age*** Age*
Age*** Stage*** Stage*
Age*** log Na*** Age*** log Urea*** Age** Age** Age** log AlkP** Chloride*
log Na*** log GGT** Albumin*** log Na*** log Na** log Na** log Na* log Na*
Sex** log Na*** Sex* Sex*
Age*
More than n = 1,310 n = 1,119 n = 972 n = 916 n = 643 n = 480 n = 502 n = 392 n = 268
6 months Stage*** Stage*** Stage*** Stage*** Stage*** Stage*** Stage*** Stage*** Stage***
PS*** PS*** PS*** PS*** log Na*** PS*** PS*** Bicarb*** PS*
log Na** log GGT*** log Na*** log AlkP** PS* log Na** log Na*
PS**
log AlkP** log Na*
PS, performance status; AlkP, alkaline phosphatase; Na, sodium; GGT, gamma glutamyl transpeptidase; AST, aspartate aminotransferase;
LDH, lactate dehydrogenase. *P<0.05, **P<0.01, ***P<0.001. The reduced models consist of those variables above the horizontal lines.
Table V Six month survival rates in the three prognosis groups in the analyses of the initial period
Prognosis A B C D E F G H I
Model group n = 1,960 n = 1,631 n = 1,452 n = 1,364 n = 940 n = 674 n = 683 n = 520 n = 360
Full 'Better' 86.9% 87.9% 87.5% 86.0% 87.3% 89.4% 90.0% 88.4% 89.3%
'Medium' 71.9% 71.4% 74.4% 73.2% 73.0% 78.5% 81.6% 81.6% 83.2%
'Worse' 46.0% 50.3% 42.7% 44.6% 44.3% 53.4% 56.4% 56.3% 50.8%
'Reduced' 'Better' 85.3% - 85.2% 84.6% 87.1% 87.1% 89.9% 87.6% -
'Medium' 72.5% 74.4% 72.9% 73.2% 80.2% 81.9% 83.3%
'Worse' 47.0% - 44.8% 46.0% 44.7% 54.3% 56.6% 55.0%
PS, AlkP, 'Better' 85.6% 86.6% 88.8% 89.1% 87.5%
stage 'Medium' 75.1% 73.8% 79.8% 82.8% 81.8%
'Worse' 48.9% 44.7% 52.9% 54.1% 53.8%
Full = all significant variables; 'reduced' = minimum set of variables giving an 'acceptable' degree of discrimination; PS,
AlkP, stage = model consisting of performance status, alkaline phosphatase and disease stage (this is only shown when the
'reduced' model does not comprise these three variables).
The nine analyses suggested that, during the 6 months
after starting treatment, the main prognostic factors were PS,
AlkP and stage, although AST or LDH could replace AlkP.
There were only 360 patients for whom age, sex, stage, PS,
AlkP, Na, ESR, plasma chloride and LDH were all known
(analysis I). Therefore, in an attempt to assess the prognostic
potential of LDH, an analysis of the larger number of
patients (639) from the Manchester and Edinburgh data for
whom age, stage, PS, AlkP, Na and LDH were all known
was also performed. PS, LDH, stage and age (in that order)
were the significant prognostic factors for the first 6 months,
although the model could be reduced to just the first three.
Nevertheless, this model could be replaced quite adequately
by one consisting of PS, AlkP and stage.
In the assessment of those patients who survived the intial
6 month period, stage, PS, Na and AlkP all contributed
significantly to the full model in analysis A (Table IV). This
model could be reduced to stage, PS and Na while still
retaining an 'acceptable' degree of discrimination (Table VI).
Disease stage and PS appeared in the full model in all nine
analyses of this later period and Na appeared in six. The
'reduced' model comprised stage, Ps and Na in five analyses
(A, C, E, F and G). In the remaining four, the only new
variable to be introduced was bicarbonate but the number of
patients in the analysis (H) was only 392. In analyses B, D
and H, a model consisting of stage, PS and Na gave a
'similar' degree of discrimination.
These results show that PS and disease stage are important
prognostic factors in both periods. However, their relative
importance changes over time with PS being paramount in
the initial period and stage in the later period. The change in
the relative importance of PS and stage and also of AlkP, Na
and age can be illustrated by calculating the risk in the other
category relative to that in the first (after categorising AlkP,
Na and age) for the time periods 0-6 months, 6-24 months
and more than two years after starting treatment (Table VII).
The primary importance of PS, AlkP and disease stage and
the secondary role of Na and age in the first 6 months is
shown by the high risk ratios. In the 6-24 month period, the
risk ratios for AlkP, Na and age are close to unity indicating
Table VI Two year survival rates in the three prognostic groups in the analyses of the later period
Prognosis A B C D E F G H I
Model group n = 1,310 n = 1,119 n = 972 n = 916 n = 643 n = 480 n = 502 n = 392 n = 268
Full 'Better' 15.8% 16.8% 15.2% 14.4% 13.9% 23.1% 24.5% 16.7% 12.5%
'Medium' 7.5% 7.3% 7.7% 6.8% 10.9% 7.2% 9.5% 10.4% 11.7%
'Worse' 2.5% 2.0% 2.5% 2.8% 2.6% 1.9% 3.3% 3.7% 3.0%
'Reduced' 'Better' 14.8% 16.1% - - - - - 17.7%
'Medium' 8.2% 7.5% - - 9.1%
'Worse' 2.8% 2.7% - 4.5%
Stage, PS, 'Better' 16.4% 15.2% 15.7% 13.5%
Na 'Medium' 7.1% 6.1% 11.8% 8.2%
'Worse' 2.8% 2.6% 2.9% 3.4%
Full = all significant variables; 'reduced' = minimum set of variables giving an 'acceptable' degree of discrimination; stage,
PS, Na = model consisting ofdisease stage, performance status and sodium (this is only shown when the 'reduced' model does
not comprise these three variables).
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Table VII Unadjusted risk ratios in three time periodsa
Upto6 6-24 >24
Variable Value months months months
Performance 1 1.00 1.00 1.00
status 2 2.07 1.34 0.61
3 4.27 1.80 0.37
Disease stage LD 1.00 1.00 1.00
ED 2.10 1.55 0.43
Alkaline < 150 u 1-l 1.00 1.00 1.00
phosphatase > 150u1- 1.60 1.14 1.13
Sodium < 136 mmol I-' 1.00 1.00 1.00
> 136mmoll-' 0.74 0.84 0.34
Age <65 years 1.00 1.00 1.00
> 65 years 1.35 0.95 1.96
aRisk ratios are calculated using data from the 1,960 patients included
in analysis A, after categorising alkaline phosphatase, sodium and age.
their lack of predictive power. The risk ratios for PS and
disease stage also decrease, but those for PS decline more
rapidly than for stage. This results in the principal prognostic
factor changing from PS in the initial period to stage in the
later period. The risk ratios for more than 24 months are less
reliable since only 104 patients in the six data sets survived
for more than 2 years.
In all the analyses, PS and stage were both categorical
variables, but AlkP was a continuous variable with a log-
transformation (the respective coefficients were 0.735, 0.693
and 0.432). A complex equation of this form would be of
little practical use for prognosis prediction in the clinical
setting. Therefore, a simple index was devised with AlkP
categorised into 'normal' (< 150 u 1-') and 'raised'
(>150 u 1'). This index was used on the 1,995 patients for
whom the values of all three variables were known. The
outcomes of the index were divided into four groups and the
6 month and 2 year survival rates for these groups were
calculated (Table VIII); the complete 2 year survival curves
are shown in Figure 1. The 6 month survival rates in groups
1 and 2 are similar, and they should perhaps be amalgamated.
This gives three prognosis groups with six month survival rates
of 81.4% (95% CI: 78.9-83.8%), 63.1% (59.4-66.8%) and
40.9% (35.9-46.0%) respectively (Table VIII).
The initial exclusion of the MRC studies turned out to be
fortuitous because it was possible to use two of them in a
validation exercise of the prognostic index. As stated
previously, certain variables were reported by some hospitals
in the MRC studies but were not computerised. One of these
was AlkP, which was reported for a high proportion of
patients in the first two MRC studies (MRCI and MRC2).
In addition, performance status in the form of an activity
status score was available in the notes of almost all the
patients in MRC1. These details were abstracted from the
patients' notes and added to the computer file. The activity
status scale used in MRC1 was not exactly the same as that
100'
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Figure I Two year survival in each prognostic group obtained
by applying the index to the original data sets ..... prognostic
group I (n = 336); prognostic group 2 (n = 651); ---
prognostic group 3 (n = 649); prognostic group 4
(n = 359).
in MRC2 (see Appendix), but it was possible to combine
them so that they were compatible with the overall PS, as
shown in Table IX.
In these two data sets, there were 480 patients for whom
PS, AlkP and disease stage were all known and Table X
summarises some of the information about these patients.
Their median age was similar to those in the other six data
sets (Table III), although the proportion aged 65 years or
more was rather low. The majority of patients in the first
trial and all patients in the second had limited disease (LD).
The overall 2 year survival rate for these 480 patients was
7.1%, slightly better than the overall rate of the other six
data sets (5.9%). The prognostic index was applied to these
480 patients (Table XI). Since only 1.9% of the patients had
a PS score of 3 and 15.2% had ED, there were only 82
patients in the two groups with the poorest prognosis. Never-
theless, the index shows a clear difference between the four
prognosis groups (Table XI and Figure 2). If prognosis
groups 1 and 2 are amalgamated as before, the six month
survival rates are 64.1% (95% CI: 59.3-68.7%), 40.4%
(28.2-53.3%) and 24.0% (10.3-42.8%) respectively. Scores
were also calculated for each of the 480 patients using the
coefficients derived in analysis A of the six data sets. Ranking
the patients by these scores and then grouping them into the
first 173 patients, the next 225, the next 57 and the remaining
25 gave the six month survival rates shown in Table XI.
Table IX Combined MRC activity status scale
PS MRCJ activity status MRC2 activity status
1 1,2 1
2 3,4 2,3
3 5 4
Table VIII The prognostic index, comprising performance status, alkaline phosphatase and disease stage, applied to the six data sets
Prognosis No. of Six month 95% Two year survival
group PS AlkP Stage patients % of totalsurvival rate confidence interval rate 95% confidence interval
1 1 <150 LD 336 16.8% 85.9% 81.8-89.3% 14.7% 11.0-19.0%
2 <150 LD 81.4%* 78.9-83.8%* 10.2%* 8.3-12.2%*
2 1 > 150 LD 651 32.6% 79.1% 75.9-82.1% 7.8% 5.9-10.1%
1 <150 ED
2 >150 LD
3 2 >150 ED 649 32.5% 63.1% 59.4-66.8% 2.3% 1.3- 3.7%
3 <150 LD
3 > 150 LD
4 23 <150 ED 3 18.0% 40.9% 35.9-46.0% 0.9% 0.2- 2.5%
3 >150 ED
Total 1995 100% 68.1% 66.1 -70.2% 5.9% 4.9- 7.1%
PS, performance status; AlkP, alkaline phosphatase. *Prognosis groups I and 2 combined.
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Table X Age, sex, disease stage, performance status and survival of the
480 patients used in the validation exercise
MRCJ MRC2 Overall
n = 311 n = 169 n =480
Median age 59 59 59
Age range 20-75 35-74 20-75
% aged 65 or more 20.7% 21.3% 20.9%
Male 73.0% 69.2% 72.0%
Female 26.0% 30.8% 28.0%
Limited disease 76.5% 100.0% 84.8%
Extensive disease 23.5% 0.0% 15.2%
Performance status
1 46.3% 57.4% 50.2%
2 51.1% 42.0% 47.9%3 2.6% 0.6% 1.9%
Two year survival rate 7.4% 6.5% 7.1%(95% confidenceinterval) (4.5-10.3%) (2.8-10.2%) (4.8-9.4%)
~0
-0
0~
I
Years since starting treatment
Figure 2 Two year survival in each prognostic group obtained
by applying the index to 480 MRC patients .... prognostic group
I (n = 173); prognostic group 2 (n = 225); - - - prognostic
group 3 (n = 57); prognostic group 4 (n = 25).
Discussion
Although data on a total of 3,873 SCLC patients were
received, it was only possible to use a maximum of 1,960 toidentify the prognostic factors due to inconsistencies in the
variables recorded and incomplete information. The individ-
ual studies were, of course, performed as independent
research projects, not with the intention of using them in an
overview analysis. The inconsistencies in the data sets meant
that the overview had to be carried out as a series of analyses
and, consequently, the results do not lead to such clear
conclusions as might have been obtained if all variables had
been measured in all the studies.
In this overview, a technique was employed in whichpatients were divided into three equal-sized groups, using theCox scores calculated from the proportional hazards regres-
sion, and survival rates of the three groups calculated. An
arbitrary range of ± 2.5% was used to decide whether the
survival rates of three equal-sized groups determined by a
subset of the prognostic factors were 'similar' to those
obtained in the full model, i.e. that consisting of all
significant factors in the analysis. This method was applied
consistently in all the analyses.
There is, however, no generally accepted statistical methodfor constructing a prognostic index and other approaches
could be used. Apart from the obvious constraint that theindex must be reasonably simple to be of any clinical use,there are various statistical and practical questions whichhave to be answered somewhat arbitrarily.1. Is the main aim to identify small subsets of patients withparticularly good or bad prognosis? We could, for example,have divided the patients into the best 10%, the worst 10%
and the remainder rather than into three equal-sized groups.2. A variable which is a statistically significant predictor of
survival may not be worth including in the prognostic index,
either because it is relevant only for a small proportion ofpatients or because the difference in survival that it predictsis small.
3. Any formal regression procedure entails implicit
assumptions (such as proportionality of hazards in the Cox
model) which are not exactly true. In these data, for instance,the predictive power of most variables fell with increasingduration of follow-up (Table VIII). We attempted to circum-
vent this technical problem by restricting the analyses to theinitial 6 months, but other approaches, including time-dependent coefficients in the Cox regression, could have been
used.
4. Many prognostic variables are intercorrelated and quitegood predictive power may be achieved even when some
strongly predictive variables are omitted. Thus, for example,Vincent et al. (1987) constructed a reasonably useful prog-
nostic index without including disease stage. The choice of
parameters on which to base a prognostic index is, therefore,
somewhat arbitrary, as similar predictive power may be
achieved with different subsets of variables.
5. Is the principal aim to predict survival at 6 months, 2
years or 5 years? Very few SCLC patients are long-term
survivors and, beyond 6 months, variables such as treatment
response, current performance status and tumour progression
are more useful predictors of long survival than the initial
variables used in this overview. This was a further reason for
our decision to base the prognostic index on survival up to 6
months, although our choice of this particular period wasinevitably somewhat arbitrary.
Table XI The prognostic index, comprising performance status, alkaline phosphatase and disease stage applied to the 480 patients used in the
validation exercise
Six month
survival rate, Six month survivalPrognosis No. of using prognostic 95% rate, using Coxgroup PS AlkP Stage patients %o,f total index confidence interval coefficients' 95% confidence interval
1 1 < 150 LD 173 36.0% 74.0% 67.1 -80.1% 74.0% 67.1 -80.1%2 <150 LD 64.1%b 59.3-68.7%b 64.1%b 59.3-68.7%b2 1 ) 150 LD 225 46.9% 56.4% 49.9-62.8% 56.4% 49.9-62.8%1 <150 ED
2 > 150 LD
3 12 <150 ED 57 11.9% 40.4% 28.2-53.3% 42.1% 29.8-55.1%I < 150 ED
3 < 150 LD
3 .--150 LD
4 3 <150 ED 25 5.2% 24.0% 10.3-42.8% 20.0% 7.7-38.2%2 .150 ED
3 .150 ED
Total 480 100% 59.2% 54.7-63.5% 59.2% 54.7-63.5%
PS, performance status; AlkP, alkaline phosphatase. aCalculated score = 0.735 x PS + 0.432 x log AlkP + 0.693 x stage. "Prognosis groups 1and 2 combined.
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There were some important differences between the
patients in the six data sets used to identify prognostic
factors, especially in PS and disease stage (Table III). This
lack of homogeneity may result from different referral rates
suggesting that different types of patients attend the different
centres. Additional variables indicating to which data set
each patient belonged were used in an attempt to take
account of these differences.
The recorded values of the biochemical variables were used
throughout the overview because normal ranges were not
available from all the various hospitals. Where they were
available, several (including AlkP) showed considerable
variation between the hospitals and better discrimination
may have been achieved if values adjusted for the individual
laboratories' normal ranges could have been used. It is,
however, difficult to assess whether such an adjustment
would have made any substantial difference to the results.
In spite of these problems, the results of the analyses of the
initial 6 month period indicate that PS, AlkP and disease
stage are the most important prognostic factors (Table IV
and V). In various subsets of the data, GGT, albumin, urea,
AST, LDH and chloride were also significant variables,
although after reduction only GGT, AST, LDH and chloride
retained their importance in the relevant analyses. When
models containing these variables were compared with one
consisting of PS, AlkP and stage, a 'similar' degree of disc-
rimination was obtained. It is possible that AST, LDH and,
perhaps, GGT may be useful prognostic factors, which sug-
gests that an adequate index is one consisting of PS, disease
stage and a liver function test; the liver function test prob-
ably acts as an indicator of disseminated disease. AlkP, AST,
GGT and LDH in the six data sets were not highly cor-
related, the strongest association being between AlkP and
GGT (Spearman rank correlation coefficient = 0.49).
A simple prognostic index for the 6 months after starting
treatment, based on the variables PS, AlkP and disease stage,
was devised for the clinical setting. This index was shown to
be effective, as one would expect, in the data from which it
was developed, both as a whole and within each study, and
was also validated in an independent data set. The survival
rates of patients in the three prognosis groups in the MRC
data were around 20% lower than the corresponding rates
derived from the other studies. This difference may be related
to the fact that both MRC studies were carried out some
years ago. Consequently, it would be useful to test the index
on a more recently collected cohort of SCLC patients. The
simple index provides a degree of discrimination which is
virtually identical to that provided by one incorporating the
coefficients derived from the Cox model (Table XI).
For those patients who survived the first 6 months, disease
stage, PS and Na appear to be the important prognostic
factors with stage being of primary importance. In addition,
AlkP, GGT and bicarbonate were also significant variables in
some of the analyses. Since the predictive power of most
variables decreased with increasing duration of follow-up, a
prognostic index for this later period based on the values of
disease stage, PS and Na (or other variables) measured at the
start of treatment is not particularly useful. A more relevant
index for this period would be one derived from the values of
PS, stage, Na, etc., measured in 6 month survivors, together
with other variables such as response to treatment during the
previous months and tumour progression. The decreasing
predictive power of prognostic factors over time is also illus-
trated by the work of Souhami and Law (1990). They
analysed the survival of patients who were alive at 2 years in
the studies included in this overview, together with 2 year
survivors in some other SCLC studies. Disease stage and age
did not have any predictive value for survival beyond 2
years.
The risk ratios for PS and stage for the patients who
survived for 2 or more years appear to indicate that the
patients with a PS score of 2 or 3 have a better prognosis
than those with a score of 1 and that those with ED have a
better prognosis than those with LD (Table VII). This is, of
course, most unlikely and is probably due to random varia-
tion. A surprisingly high proportion (39%) of the 104 two
year survivors had a PS score of 2 or 3, while 19% were
recorded as having ED; even higher proportions were found
in some of the individual data sets. The different performance
status scales used in the studies, which led to the derivation
of an overall PS scale, may have reduced the prognostic
efficiency of this variable. However, it is also likely that the
high (and varying) proportions of 2 year survivors with a PS
score of 2 or 3 and with ED indicate that standard criteria
for these two variables may not have been applied in all
hospitals.
There was certainly some variation in the evaluation of
disease stage in the individual studies (Allan et al., 1984;
Cerny et al., 1987; Cullen et al., 1986; MRC Lung Cancer
Working Party, 1979, 1981, 1983; Smyth et al., 1986;
Souhami et al., 1984, 1985; Vincent et al., 1987). However, in
general, the more complex tests and investigations, e.g. liver
ultrasound scans, radioisotopic bone scans, bone marrow
aspiration and CT scans, were only performed if there was
clinical suspicion or 'plain' radiological evidence of extension
beyond LD. Some of the investigations used to evaluate
disease stage are time-consuming and unpleasant for the
patient and, for this reason, Vincent et al. (1987) deliberately
excluded stage from their attempt to devise a simple prognos-
tic index. It should, nevertheless, be noted that there were
important differences in survival between patients with LD
and ED in their data. In an attempt to assess the value of
disease stage, the nine analyses of the initial 6 month period
(Tables IV and V) were re-performed omitting this variable.
In the first analysis, it was found that a 'reduced' model
consisting of PS and AlkP provided similar but not as good
discrimination as that obtained with PS, AlkP and stage.
However, unlike the original analyses which indicated quite
consistently that PS, AlkP and stage were the most important
variables, the results of the analyses omitting stage did not
consistenly suggest a particular model that would act as a
useful substitute. In all these analyses, the omission of stage
reduced the degree of discrimination between the 'better' and
'medium' groups. Disease stage is the principal prognostic
factor beyond 6 months and, therefore, this variable should
not be omitted from any prognostic prediction for this period
based on pretreatment measurements. Consequently, it is
suggested that stage should continue to be assessed.
This overview has shown that, in the short-term (the 6
months after starting treatment), there are three groups of
variables that are of importance for prognosis prediction.
The first consists of PS, AlkP and disease stage which have
been identified as being of primary importance. The second
group comprises age, sex, Na, GGT, albumin, urea and
chloride; these variables significantly improved the goodness
of fit in the proportional hazards regression analyses, but the
improvement in the prediction of survival obtained by their
inclusion was small. LDH and AST form the third group;
they are potentially important prognostic factors, but the
relatively small numbers of patients for whom these
measurements were available prevented any definitive con-
clusions about their role. In the longer term (6-24 months),
stage, PS and Na are the significant variables, although stage
appears to be the most important.
These results, therefore, led the Subcommittee to recom-
mend that in future SCLC studies, performance status,
disease stage, AlkP, Na, AST and LDH should be recorded;
in addition, it is preferable that GGT, albumin, urea, plasma
chloride and blood bicarbonate should also be measured. It
should be stressed, however, that standard criteria must be
applied meticulously when determing performance status and
disease stage. The recording of the recommended
measurements would allow standardised comparisons
between new studies and possibly the selection of patients for
different treatment strategies. It would also facilitate another
overview of SCLC studies at some future date which should
validate the present analysis and lead to more definite con-
clusions about prognostic factors for this disease.
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Appendix
Activity status scale used in MRCI
1. At work or active retirement
2. Full activity but not at work
3. Out and about but activity restricted
4. Confined at home or hospital
5. Bedridden
Activity status scale used in MRC2
1. Normal activity
2. Activity restricted
3. Confined to home/hospital
4. Bedridden
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